Core Viewpoint - The stock of Baiaosaitu-B (02315) surged over 15% in early trading, driven by the upcoming IPO on the STAR Market and a recent partnership with Merck for antibody development [1] Group 1: IPO Details - Baiaosaitu plans to raise 1.185 billion yuan through its STAR Market IPO, with funds allocated for early drug development services, antibody drug research, preclinical and clinical research projects, and to supplement working capital [1] - The IPO review is scheduled for September 24, marking a critical milestone for the company [1] Group 2: Partnership with Merck - Earlier this month, Baiaosaitu signed an evaluation agreement with Merck to develop antibody-conjugated lipid delivery solutions for nucleic acid drugs [1] - Under the agreement, Baiaosaitu will provide fully human antibodies developed on its RenMice platform for Merck to assess their feasibility for antibody-conjugated lipid nanoparticle formulations [1] - Merck has been granted exclusive rights to acquire selected antibody assets, while Baiaosaitu is entitled to receive corresponding fee payments, sales shares, and sublicensing royalties [1]

Core Viewpoint - Baiaosaitu-B (02315) has seen a significant stock price increase, with a rise of over 15% in early trading, currently up 11.41% at HKD 27.74, with a trading volume of HKD 12.0264 million [1] Group 1: IPO and Fundraising - The Shanghai Stock Exchange's listing review committee announced that Baiaosaitu's IPO on the Sci-Tech Innovation Board will be reviewed on September 24 [1] - The company plans to raise HKD 1.185 billion through this IPO, which will be allocated to the construction of an early drug development service platform, antibody drug research and evaluation projects, preclinical and clinical research projects, and to supplement working capital [1] Group 2: Collaboration with Merck - Earlier this month, Baiaosaitu signed an antibody selection assessment agreement with Merck, a leading global technology company, to advance the development of antibody-conjugated lipid delivery solutions for nucleic acid drugs, such as antibody-conjugated lipid nanoparticles (LNP) [1] - Under the agreement, Baiaosaitu will provide fully human antibodies developed on its RenMice platform for Merck to evaluate their feasibility for use in antibody-conjugated LNP formulation services [1] - Merck has been granted exclusive rights to acquire selected antibody asset rights, while Baiaosaitu is entitled to receive corresponding fee payments, sales shares, and sublicensing shares [1]

Core Viewpoint - Baiaosaitu-B (02315) has seen a significant stock price increase, attributed to its upcoming IPO on the STAR Market, which is set to raise approximately 1.185 billion yuan for various R&D projects and working capital [1] Group 1: Stock Performance - Baiaosaitu-B's stock rose over 15% in early trading, currently up 11.41% at 27.74 HKD with a trading volume of 12.0264 million HKD [1] Group 2: IPO Details - The IPO is scheduled for review on September 24, with plans to raise 1.185 billion yuan [1] - The funds will be allocated to the construction of a drug early-stage R&D service platform, antibody drug R&D and evaluation projects, preclinical and clinical R&D projects, and to supplement working capital [1] Group 3: Strategic Partnership - Baiaosaitu has signed an evaluation agreement with Merck to develop antibody-conjugated lipid delivery solutions for nucleic acid drugs [1] - Under the agreement, Baiaosaitu will provide fully human antibodies developed on its RenMice® platform for Merck to assess their feasibility for antibody-conjugated lipid nanoparticle formulations [1] - Merck has exclusive rights to acquire selected antibody assets, while Baiaosaitu is entitled to receive corresponding fee payments, sales shares, and sublicensing shares [1]

特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们的推送。 近期，默克发布了一则关于被冒用用于欺诈行为的声明： 默克中国 近期，我们注意到有不法分子通过伪造APP，冒用默克的名义，发布所谓"民间投融资"的不实信息，造成公众财产损 失。对此，默克中国（以下简称"默克"）郑重声明如下： 1 、 上 述 APP 及 其 宣 传 资 料 与 默 克 无 任 何 关 联 ， 属 冒 用 与 欺 诈 行 为 。 作 为 在 德 国 上 市 的 企 业 ， 默 克 从 未 也 不 会 通 过 APP、社交媒体或个人渠道，面向社会公众开展任何形式的民间融资或投资募集。 2、相关APP中使用的标识、模板及"公司介绍"等内容并非由我司制作或授权。请以默克官网与"默克Merck"官方微 信公众号发布的信息为准。 3、我司已第一时间将相关线索向国家有关部门反映，并将依法持续提供协助。我们呼吁受影响的公众尽快向当地公安 机关或反诈中心报案，并妥善保存转账记录、聊天记录、APP下载信息等证据。 4、对于任何未经授权使用我司名称、商标及资料的行为，默克保留依法追究法律责任的权利。 ...

Core Viewpoint - BMS is selling its 60% stake in Shanghai BMS Pharmaceutical Co., Ltd. to an affiliate of Hillhouse Capital, with the transaction expected to be completed by early 2026, as part of its long-term strategic resource allocation in response to evolving business needs [1][2]. Group 1: Company Strategy - The sale of the stake in SASS reflects BMS's commitment to its production strategy, aiming to balance internal resources through strong external partnerships and deepen regional strategic layouts [1]. - BMS maintains a strong commitment to the Chinese market and plans to continue investing under its "China 2030 Strategy," focusing on accelerating the introduction of innovative therapies and improving drug accessibility for patients [1][4]. Group 2: Industry Context - Shanghai BMS, established in 1982, is the first Sino-American joint venture pharmaceutical company in China, with BMS holding 60% of the shares, Shanghai Pharmaceutical Group 30%, and China National Pharmaceutical Group 10% [2]. - The trend of joint venture pharmaceutical companies exiting the Chinese market is evident, with examples including Johnson & Johnson's rebranding of Xi'an Janssen and Hengrui's acquisition of the remaining shares of MSD [2][3]. - The exit of these joint ventures marks the end of an era, as they previously provided many classic drugs to the Chinese market, but the current market is now filled with more cost-effective generic alternatives [3]. Group 3: Future Outlook - The departure of joint venture companies does not indicate a complete exit of foreign pharmaceutical companies from the Chinese market; instead, many are refocusing on innovative drug businesses and introducing more innovative products in China [4]. - Concerns about the potential withdrawal of classic drugs from the market are mitigated by the expectation that these products will transition to new companies, which may revitalize their market presence [4].

Core Viewpoint - The stock of Baiaosaitu-B (02135) has seen a significant increase of over 7% in the afternoon trading session, attributed to recent licensing agreements with Tubulis and Merck, highlighting the company's competitive edge in the antibody development sector [1] Group 1: Licensing Agreements - On September 16, Baiaosaitu announced a licensing agreement with German ADC developer Tubulis, utilizing its proprietary RenMice fully human antibody development platform for innovative ADC therapies [1] - Under the agreement with Tubulis, Baiaosaitu will receive an upfront payment, milestone payments related to development, regulatory, and commercialization, as well as a single-digit percentage of net sales [1] - Earlier, on September 4, Baiaosaitu signed an antibody option and evaluation agreement with Merck, focusing on evaluating antibodies developed from the RenMice platform for advanced solutions like nucleic acid drug delivery [1] Group 2: Market Performance - As of the report, Baiaosaitu's stock price is at 26.58 HKD, with a trading volume of 16.7354 million HKD, reflecting a 4.07% increase at the time of publication [1] - The recent agreements with Tubulis and Merck underscore the international competitiveness and drug conversion potential of Baiaosaitu's fully human antibody platform, as stated by the company's Chairman and CEO, Shen Yulei [1]

Core Viewpoint - Shunyi District has become a significant hub for high-end manufacturing in Beijing, particularly in the fields of new energy vehicles, aerospace, semiconductors, intelligent equipment, and healthcare, with industrial output growing at an average annual rate of 8.2% since the 14th Five-Year Plan, reaching nearly 200 billion yuan last year [1][4]. Group 1: Economic Growth - Shunyi District's GDP has grown at an average annual rate of 5.8% since the 14th Five-Year Plan, totaling 238.8 billion yuan last year [3]. - Fixed asset investment has increased at an average annual rate of 6.5%, surpassing 60 billion yuan last year [3]. Group 2: High-End Manufacturing Development - The new energy vehicle sector in Shunyi has attracted major manufacturers such as Li Auto, Beijing Hyundai, and Mercedes-Benz, producing 1.65 million vehicles with an output value of 336 billion yuan, growing at an average annual rate of 13% [4]. - The aerospace industry has seen an average annual industrial output growth of 15%, with over 20 key enterprises and a significant presence in aircraft maintenance, contributing 14 billion yuan to the industrial output [5]. - The pharmaceutical trade sector has gathered leading companies like Sinopharm and Merck, with a trade scale exceeding 100 billion yuan for two consecutive years, accounting for nearly one-third of the national total [5][6]. Group 3: Open Development Platforms - Shunyi District hosts over 950 foreign-funded enterprises, with the Capital Airport Economic Zone being a key area, generating over 350 billion yuan in revenue last year, a 53% increase from 2020 [6]. - The Tianzhu Comprehensive Bonded Zone ranks highly among national bonded zones, while the Sino-German Industrial Park has attracted over 120 German-funded enterprises [6]. Group 4: Social Investment and Employment - Over 85% of Shunyi's fiscal spending is allocated to social welfare, with 22 billion yuan invested in education over the past five years [8]. - The district has created 170,000 new jobs in five years and has been recognized as a "fully employed district" in Beijing for 13 consecutive years [8].

Economic Growth and Investment - Shunyi District's GDP has averaged a growth of 5.8% since the 14th Five-Year Plan, reaching a total of 238.8 billion yuan last year [1] - Fixed asset investment has averaged a growth of 6.5%, surpassing 60 billion yuan last year [1] - Industrial output has averaged a growth of 8.2%, with nearly 200 billion yuan in total last year, ranking among the top three in the city [1] Automotive Industry - Shunyi produces one out of every three cars in Beijing, with a cumulative production of 1.65 million vehicles and an output value of 336 billion yuan since the 14th Five-Year Plan, growing at an annual rate of 13% [2] - The district is developing a 2,500-acre intelligent connected new energy vehicle technology ecological park to support the industry [2] Aerospace and Pharmaceutical Industries - Shunyi is home to over 220 aviation service companies, generating nearly 200 billion yuan in revenue last year, an 86% increase from 2020 [3] - The pharmaceutical sector includes over 110 regulated enterprises, with a manufacturing output exceeding 10 billion yuan and a trade scale reaching 100 billion yuan [3] Internationalization and Urban Development - Shunyi is focusing on building an international new city, enhancing international community, education, and medical facilities [4] - The district has nearly 10,000 foreign residents and 11 international schools, with a significant number of students entering top 100 universities by 2025 [5][6] Infrastructure and Environmental Improvements - Shunyi has nearly 3,000 kilometers of roads, leading the city in road network density, and is working on major projects for better connectivity [8] - The district has achieved a 30% reduction in PM2.5 levels since 2020 and has increased green coverage significantly [8] Social Welfare and Community Engagement - Over 85% of Shunyi's fiscal spending is allocated to social welfare, with significant investments in education and healthcare [7] - The district has implemented various measures to enhance community spirit and support for residents, including recognition programs for good deeds [9]

Investment Rating - The investment rating for the pharmaceutical and biotechnology industry is "Positive" and the rating has been maintained [2] Core Views - The pharmaceutical and biotechnology industry index increased by 1.03% during the reporting period, outperforming the CSI 300 index which rose by 0.56% [3][16] - The industry valuation as of September 12, 2025, shows a PE (TTM overall method, excluding negative values) of 31.79x, up from 31.41x in the previous period, indicating an upward trend but still below the average [4][22] - Recent academic conferences and industry dynamics highlight the strength and resilience of China's innovative drug development capabilities [7][8] Industry Trends - The top-performing sub-industries include other biological products and medical research outsourcing, with increases of 4.17% and 3.64% respectively, while traditional Chinese medicine and hospitals saw declines of 1.36% and 1.23% [3][16] - A total of 48 listed companies in the pharmaceutical and biotechnology sector experienced a net reduction in shareholder holdings amounting to 3.686 billion yuan, with 6 companies increasing their holdings by 406 million yuan and 42 companies reducing by 4.092 billion yuan [4] Important Industry News - The NMPA has optimized the review and approval process for clinical trials of innovative drugs, aiming to enhance the efficiency of clinical research [26][27] - Sanofi's Teplizumab has been approved by the NMPA as the first innovative drug to delay the progression of type 1 diabetes [37][38] - The U.S. government is considering strict restrictions on Chinese pharmaceuticals, which may impact the industry [49][50] Investment Recommendations - Investors are advised to focus on companies with differentiated advantages in innovative pipelines, particularly in oncology, autoimmune, and metabolic disease areas [8] - Companies with international standard clinical and data capabilities, as well as those with mature license-out capabilities and global collaboration resources, are also recommended for investment [8]

Core Insights - The company, Baiaosaitu, has signed an antibody option and evaluation agreement with German pharmaceutical Merck to jointly develop cutting-edge solutions for nucleic acid drug delivery using antibody-conjugated lipid nanoparticles (LNP) [1] - The agreement allows Merck to evaluate Baiaosaitu's fully human antibodies developed through its proprietary RenMice platform, with Merck having the option for global exclusive rights to selected antibodies [1] - Baiaosaitu's CEO highlighted the potential of the antibody-conjugated delivery system and the broad application prospects of fully human antibodies beyond traditional therapies [1] Financial Performance - In the first half of 2025, Baiaosaitu reported a revenue of 621 million yuan, representing a year-on-year growth of 51.3%, with nearly 70% of revenue coming from overseas collaborations [1] - The company has signed a total of 280 external licensing agreements, with 80 new agreements in the first half of the year, marking a 60% increase compared to the same period last year [1] Research and Development - Baiaosaitu has maintained high R&D investment, with R&D expenses of approximately 209 million yuan in the first half of the year, an increase of 29.3% year-on-year [2] - The company employs around 400 researchers focused on the "Thousand Mice, Ten Thousand Antibodies" initiative and preclinical research [2] - As of June 30, Baiaosaitu has obtained 195 authorized patents and submitted 496 patent applications, with plans to expand its fully human antibody library [2] Company Background - Established in 2009, Baiaosaitu began with target humanized model animals and gradually entered the fully human antibody development business [2] - The company launched the "Thousand Mice, Ten Thousand Antibodies" program in 2020 to create an "antibody shelf" and develop various advanced antibody products [2] - Baiaosaitu has become a leader in China's innovative molecular licensing, leveraging its proprietary fully human antibody mouse platform, RenMice [2]